Study of VGX-100 Administered Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced Solid Tumors

Phase 1

Completed

• Conditions: Neoplasms; Cancer
• Interventions: Drug: VGX-100; Drug: Bevacizumab

• Registration Number: NCT01514123
• Lead Sponsor: Circadian Technologies Ltd.

Brief Summary

This is a non-randomized, multi-dose, first-in-human, multicenter, two arm (Arm A: VGX-100 alone; Arm B: VGX-100 co-administered with bevacizumab), open label, dose escalation study in subjects with advanced or metastatic solid tumors. The study is aimed at evaluating the safety and establishing the recommended dose of the VEGF-C human monoclonal antibody VGX-100 when administered alone or in combination with bevacizumab.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-12-29
• Study First Submitted: 2012-01-12
• Study First Submitted QC: 2012-01-19
• Study First Posted: 2012-01-20
• Primary Completion: 2014-02-07
• Study Completion: 2017-11-16
• Status Verified: 2020-09
• Last Update Submitted: 2020-09-16
• Last Update Posted: 2020-09-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 43

Inclusion Criteria

• Age ≥ 18 years
• Provision of written informed consent
• Histologically or cytologically documented advanced or metastatic solid tumor that is refractory to standard treatment, for which no standard therapy is available, or for which the subject refuses standard therapy
• Life expectancy > 3 months in the opinion of the investigator
• ECOG performance status 0 to 1
• Evaluable OR measurable disease by RECIST 1.1 criteria
• Agree to the use of effective contraceptive if either male or female of child bearing potential

Read More

Exclusion Criteria

• Inadequate venous access

• Women who are lactating/breastfeeding

• Women with a positive pregnancy test or who are planning to become pregnant during the duration of the study

• Known to be HIV positive, or have chronic hepatitis B or C

• Major surgical procedure within 6 weeks of Baseline or surgical or other wound that is not fully healed at Baseline

• Untreated or symptomatic brain metastasis, known central nervous system metastasis, or spinal cord compression (except glioblastoma multiforme)

• Mediastinal or cavitated, or lung mass located near, invading or encasing a major blood vessel or airway on imaging

• Squamous cell lung cancer

• History of or known/suspected gastrointestinal perforation

• Hemoptysis of >2.5 mL (half a teaspoon) red blood within 28 days of Screening

• Deep venous thrombosis or history of symptomatic pulmonary thromboembolism within 6 months of Screening

• Gastrointestinal bleeding requiring medical intervention within 28 days of Screening

• Receipt of therapeutic concentrations of warfarin or other anticoagulants within 7 days of Screening

• Receipt of investigational agent(s) for any indication within 28 days of Baseline or 5 half lives, whichever is greater

• Receipt of the following treatments:

  • Traditional cytotoxics, tyrosine kinase inhibitors or other small molecule anti-cancer agents within 21 days
  • Nitrosoureas, mitomycin C, bevacizumab or trastuzumab within 6 weeks
  • Any other therapeutic monoclonal antibodies within 21 days
  • Hormonal therapy (other than gonadal suppression) within 14 days

• Radiotherapy:

  • to >25% bone marrow
  • to brain within 28 days of baseline
  • other than above within 14 days of baseline

• Unstable angina, myocardial infarction, transient ischemic events, or stroke within 24 weeks of Screening

• History of CNS hemorrhage, cerebrovascular hemorrhage, myocardial infarction or reversible posterior leukoencephalopathy syndrome associated with prior anti-VEGF/anti-VEGFR therapy

• Uncontrolled hypertension of ≥ CTCAE Grade 2

• Proteinuria at Baseline of ≥2+ or 1.0g/24 hours

• Prior allergic reaction to a monoclonal antibody

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Arm A - VGX-100 alone	VGX-100	Dose escalation of VGX-100 monotherapy
Arm B - VGX-100 plus bevacizumab	VGX-100	Dose escalation of VGX-100 in combination with escalating doses of bevacizumab
Arm B - VGX-100 plus bevacizumab	Bevacizumab	Dose escalation of VGX-100 in combination with escalating doses of bevacizumab

Primary Outcome Measures

Name	Time	Method
The incidence and severity of adverse events including dose limiting toxicities	Approximately 16 months

Secondary Outcome Measures

Name	Time	Method
Anti-VGX-100 antibody formation	Approximately 16 months
Pharmacokinetic parameters of VGX-100 alone and co-administered with bevacizumab including Cmax, Cmin, AUC and if feasible half life (t1/2)	28 days after the last subject in each cohort
Tumor response by RECIST criteria	Approximately 16 months	Tumor response assessment will be measured by computated tomography (CT) or Magnetic resonance imaging (MRI) every 8 or 12 weeks throughout the study
Biomarker levels including VEGF-A, VEGF-C, VEGF-D, soluble VEGFR-2, and soluble VEGFR-3	Approximately 16 months

Trial Locations

Locations (2)

UCLA Hematology-Oncology; 🇺🇸 Santa Monica, California, United States

UT MD Anderson Cancer Center; 🇺🇸 Houston, Texas, United States